NEWS
Tempest Therapeutics Reported Amezalpat (TPST-1120) Arm Improves All Efficacy Endpoints Vs. SoC Control In Study Of Amezalpat (TPST 1120) In First Line Hepatocellular Carcinoma
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1074Followers
68Following
7377Visitors
Follow